Literature DB >> 21102312

Cardioprotective effects of perioperative β-blockade in vascular surgery patients: fact or fiction?

Suzanne Flier1, Wolfgang F Buhre, Wilton A van Klei.   

Abstract

PURPOSE OF REVIEW: Perioperative β-blockade remains a subject of debate. In this review, recent literature and current guidelines for perioperative β-blockade in vascular surgery patients are discussed. RECENT
FINDINGS: Available evidence suggests that perioperative β-blockade may be beneficial in reducing cardiac events. However, in a recent large study, the incidences of stroke and mortality were increased in patients on perioperative β-blockers. Large systematic reviews failed to demonstrate a net beneficial effect of perioperative β-blockers. The 2009 American and the European guidelines for perioperative β-blockade in vascular surgery disagree on the available evidence but do recommend β-blockade for several indications. Most recent, Wallace and colleagues published a large-sized retrospective study, reporting a beneficial effect of the adoption of a protocol for perioperative β-blockade.
SUMMARY: Perioperative β-blockade reduces cardiac events, but at the expense of increased risk for mortality and stroke. The guidelines seem to be eager to follow positive outcome studies, without considering the effects of β-blockade on other organ systems. Perhaps the main reason for the reported cardioprotective effects of perioperative β-blocker therapy should be sought in failing preoperative β-blocker prophylaxis (irrespective of surgery).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21102312     DOI: 10.1097/ACO.0b013e328341de8a

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  1 in total

1.  Incidence of Myocardial Infarction After High-Risk Vascular Operations in Adults.

Authors:  Yen-Yi Juo; Aditya Mantha; Ramin Ebrahimi; Boback Ziaeian; Peyman Benharash
Journal:  JAMA Surg       Date:  2017-11-15       Impact factor: 14.766

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.